Talking about PrEP with your partner can open up a can of worms. Here's how to make the conversation as smooth as possible.
27 January 2015 | HIV Plus
Designed to help prevent the spread of HIV/AIDS in sub-Saharan Africa and India, MEMSCap smart electronic medication packaging system tracks each time the medication bottle is opened.
26 January 2015 | Packaging World
After decades of education and advocacy, it would be reasonable to assume, that the notion of dirtiness in relation to HIV has diminished from our society. However, I would argue that this is not the case, especially if we look into dating apps / websites and the deployment of PrEP.
26 January 2015 | JZ (blog)
For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.
16 January 2015 | AIDSMeds
Two new studies, including one conducted by researchers at the Aaron Diamond AIDS Research Center (ADARC) and Rockefeller University, published today (January 15) in Science Translational Medicine, show that long-acting cabotegravir injections are highly protective in a monkey model of vaginal transmission of a virus similar to HIV.
This study was first reported by Aidsmap last year - see http://www.aidsmap.com/Monkey-studies-confirm-viability-of-injectable-PrEP-drug/page/2832825/ . A study in humans in now underway.
16 January 2015 | Rockefeller University press release
A common objection to the use of pre-exposure prophylaxis (PrEP) is that taking a pill to prevent HIV does not guard against other STI’s and therefore condoms must continue to be used. But when did avoiding every possible STI become the new goal for gay sexual behavior? Syphilis, chlamydia, and gonorrhea are all easily treated and cured.
14 January 2015 | My Fabulous Disease
To boost awareness of pre- and post-exposure prophylaxis (PrEP and PEP) to prevent HIV infection, the NYC Department of Health has launched an outreach program targeted to 600 doctors.
14 January 2015 | Poz magazine news
Peter Staley: The treatment to prevent HIV infections faces inaccurate comparisons to other meds and the same fearful objections as ‘the pill’ did in the ’60s.
07 January 2015 | The Advocate
Preexposure prophylaxis (PrEP) with tenofovir or tenofovir/emtricitabine proved as effective in women using the injectable hormonal contraceptive depot medroxyprogesterone acetate (DMPA) as in women using no hormonal contraceptive. The same proved true of men whose female sex partners were using DMPA.
07 January 2015 | International AIDS Society
Reports of sex workers misusing HIV drugs have left activists wondering if the government invested enough in HIV education before purchasing medicine, worth 4 billion Kenyan shilling. Many sex workers say clients prefer to have unprotected sex and will pay more money for it. This being a business, the women often choose to have unprotected sex, then rush to a public hospital for post-exposure prophylaxis medication, claiming they have been raped or had a burst condom. Some sex workers have also expressed uncertainties about the sustainability of the project, so they go to different hospitals and stockpile the medication, just in case it is no longer available in public hospitals.
07 January 2015 | Key Correspondents